Department of Defense Duchenne Muscular Dystrophy Research Program
July 13, 2011 leilanifera

Liestal, Switzerland, August 24, 2011 – Santhera Pharmaceuticals (SIX: SANN) announced today that the United States Patent and Trademark Office granted patent protection for the use of idebenone (brand name Catena®) in the treatment of Duchenne Muscular Dystrophy and other muscular dystrophies. The patent in the United States is supplemented by a similar patent in the European Union granted in 2010.